Arthex Biotech adds Dr Alain Huriez to its Board along with securing €4.25m funding led by Advent France Biotechnology and Invivo Ventures

– SPAIN, Valencia –  Arthex Biotech, a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1, today announced the closing of a funding round of €4.25 million led by by Advent France Biotechnology and Invivo Ventures.…